



Universiteit
Leiden
The Netherlands

Schistosome infection is associated with high-risk human papillomavirus persistence, together with altered cervicovaginal microbiota

Mukerebe, C.; Cordeiro, A.A.; Aristide, C.; Colombe, S.; Bullington, B.W.; Kalluvya, S.; ... ;
Downs, J.A.

Citation

Mukerebe, C., Cordeiro, A. A., Aristide, C., Colombe, S., Bullington, B. W., Kalluvya, S., ...
Downs, J. A. (2025). Schistosome infection is associated with high-risk human
papillomavirus persistence, together with altered cervicovaginal microbiota. *The Journal
Of Infectious Diseases*, 233(2), 375-380. doi:10.1093/infdis/jiaf447

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4297890>

Note: To cite this publication please use the final published version (if applicable).

Schistosome Infection is Associated With High-Risk Human Papillomavirus Persistence, Together With Altered Cervicovaginal Microbiota

Crispin Mukerebe,^{1,2} Alexandra A. Cordeiro,³ Christine Aristide,³ Soledad Colombe,^{3,4} Brooke W. Bullington,^{3,5} Samuel Kalluvya,⁶ Govert J. van Dam,⁷ Claudia J. de Dood,⁸ Paul L. A. M. Corstjens,⁸ Jane K. Maganga,¹ John M. Chagalucha,¹ Lucy A. Namkinga,⁹ Victor Anacleto Makene,² Myung Hee Lee,³ and Jennifer A. Downs^{1,3,6}

¹Mwanza Intervention Trials Unit/National Institute for Medical Research, Mwanza, Tanzania; ²Department of Molecular Biology and Biotechnology, College of Natural and Applied Sciences, University of Dar es Salaam, Dar es Salaam, Tanzania; ³Center for Global Health, Weill Cornell Medicine, New York, New York, USA; ⁴Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium; ⁵Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, USA; ⁶Department of Medicine, Weill Bugando School of Medicine, Mwanza, Tanzania; ⁷Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands; ⁸Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands; and ⁹St. Francis College of Health and Allied Sciences, Department of Internal Medicine, Pharmacology and Psychiatry, Ifakara, Tanzania

Schistosoma haematobium infection may impair female genital mucosal antiviral defense. We sought to determine whether women with *S. haematobium* infection had higher odds of high-risk human papillomavirus (HR-HPV) persistence, a prerequisite to cervical cancer. We also examined cervicovaginal dysbiosis, which has been linked to HR-HPV persistence and schistosome infection. In 96 Tanzanian women with baseline and 9- to 12-month follow-up samples, we performed HPV genotyping, schistosome antigen quantification, and 16S rRNA sequencing. Both *S. haematobium* (odds ratio: 4.7 [1.3–16.5], $P = .017$) and *Gardnerella*-dominant microbiome ($P = .049$) were associated with HR-HPV persistence, suggesting these factors may contribute to high cervical cancer rates in Africa.

Keywords. *S. haematobium*; high-risk human papillomavirus; cervicovaginal dysbiosis.

An estimated 100 million girls and women suffer from schistosome infections in Africa [1]. Parasitic *Schistosoma haematobium* and *Schistosoma mansoni* worms reside in venules of the urogenital and gastrointestinal tracts and lay eggs that migrate through mucosal tissue, inducing a host immune reaction

and secreting proteolytic enzymes that damage tissue. When the genital tract is involved, known as female genital schistosomiasis (FGS), sequelae include mucosal breaches, bleeding, and long-term fibrosis [2]. Further, human and animal studies have demonstrated that schistosomes impair host mucosal antiviral control, potentially allowing viruses that infect mucosal tissue to persist and flourish [3, 4].

We and others have hypothesized that, through its effects on the genital mucosal immunity, *S. haematobium* infection may promote high-risk human papillomavirus (HR-HPV) persistence, defined as detection of the same HR-HPV genotype in an individual at 2 time points at least 6 months apart [5]. Persistence of HPV infection in the cervix occurs in approximately 10–20% of women who acquire HPV [5], and contributes to nearly all cases of cervical cancer. *Schistosoma haematobium* eggs are a Group I carcinogen causing squamous cell carcinoma of the urinary bladder, but whether and how they contribute to cervical cancer is not well understood. Limited data exist describing HR-HPV prevalence and persistence in the context of FGS, and evidence on their association is mixed. A recent systematic review concluded that, while there may be associations between prevalent HR-HPV or cervical precancer and *S. haematobium*, limited and inconsistent evidence precludes definite conclusions [6]. Additionally, cervicovaginal dysbiosis has been linked to both HPV persistence and schistosome infection [7, 8].

To quantify the association of both *S. haematobium* and *S. mansoni* infection with HR-HPV persistence, we analyzed prospectively collected biobanked samples. We assessed schistosome infection overall, and hypothesized a priori that *S. haematobium* infection, which preferentially affects the genital tract, would be most strongly associated with HR-HPV persistence. We further leveraged cervicovaginal microbiota data from the same cohort to assess for the association of non-*Lactobacillus*-dominant microbiota with HR-HPV persistence.

METHODS

Past Prospective Study

Procedures for original data collection between July 2017 and September 2019 have been described [8]. Briefly, women were enrolled into two 12-month cohorts: 1 from communities endemic with *S. mansoni* and <2% *S. haematobium*, and 1 from communities endemic with *S. haematobium* and <2% *S. mansoni*. In each cohort, approximately equal numbers of women with and without schistosome infection were enrolled. Pregnant women were excluded due to the need to sample the cervix.

Baseline sociodemographic and clinical data were recorded. At quarterly visits, we collected blood for voluntary HIV counseling

Received 20 May 2025; editorial decision 19 August 2025; accepted 20 August 2025; published online 22 August 2025

Correspondence: Crispin Mukerebe, BMIS, Mwanza Intervention Trials Unit/National Institute for Medical Research, 14, International School Road, 33104, Mwanza, Tanzania (crispinmukerebe@yahoo.com).

The Journal of Infectious Diseases® 2026;233:375–80

© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
https://doi.org/10.1093/infdis/jiaf447

and testing and schistosome circulating anodic antigen (CAA) testing, urine, and stool. Gynecologic examinations included swab collection for sexually transmitted infection (STI) testing and 16S rRNA sequencing of cervicovaginal microbiota.

To test our primary hypothesis that schistosome infection was associated with HR-HPV persistence, we compared schistosome infection and other genital infections between those with and without HR-HPV. Women with HIV were excluded from analysis given its known association with HR-HPV persistence.

Study Definitions

We defined HR-HPV as the HPV types associated with cervical cancer. These included 12 types consistently classified as high risk for cervical cancer (HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, and HPV-59), 1 probable high-risk type (HPV-68), and 7 possible high-risk types (HPV-26, HPV-53, HPV-66, HPV-69, HPV-70, HPV-73, and HPV-82) [9, 10]. The assay also quantified 8 low-risk types: HPV-6, HPV-11, HPV-40, HPV-42, HPV-43, HPV-44, HPV-54, and HPV-61.

We defined schistosome infection as serum CAA ≥ 30 pg/mL using up-converting reporter particle technology with the dry SCAA20 lateral flow assay performed at the National Institute for Medical Research (NIMR) laboratory in Mwanza [11]. Urine filtration and Kato Katz stool preparations were examined microscopically for schistosome eggs. Women who were CAA positive but microscopy egg-negative were assumed to have the schistosome species most dominant in their community. All participants with eggs or CAA positivity received praziquantel as soon as either was detected.

HPV Type Testing

DNA was extracted from baseline and 9- or 12-month (end-line) endocervical swabs for retrospective HPV detection and genotyping with the Allplex HPV28 kit (Seegene, Korea) using a CFX96 Dx real-time multiplex PCR system (Bio-Rad Laboratories, USA). We defined HPV persistence as the presence of the same HPV genotype at baseline and end-line.

STI Testing

Vaginal swabs were tested on-site for *Trichomonas vaginalis* (OSOM® rapid test, Sekisui Diagnostics, USA). Cervicovaginal swabs had DNA extracted by QIAamp DNA mini-kit (Qiagen, Germany), and qPCR to detect *Chlamydia trachomatis* and *Neisseria gonorrhea* DNA was performed using the artus CT/NG QS-RGQ kit and Rotor-Gene Q system (Qiagen). Extractions and PCRs were performed in the NIMR-Mwanza laboratory. STIs were treated free of charge.

16S rRNA Sequencing

We sequenced 16S rRNA from baseline cervicovaginal swabs, as previously described [8]. Briefly, cervicovaginal COPAN

ESwabs™ (ThermoScientific, USA), kept at -80°C until analysis, had DNA extracted by phenol/chloroform/isoamyl and the 16S rRNA gene amplified. Libraries were prepared with TruSeq DNA library preparation kit (Illumina, USA) and sequenced on the Illumina MiSeq platform using a paired-end 250×250 -bp kit. The DADA2 pipeline was used for amplicon sequence variant grouping [8].

Statistical Analysis

We compared characteristics between those with and without HR-HPV persistence using logistic regression or Fisher's exact test if any cell count was <5 . Multivariable models were not pursued to maintain an appropriate events-per-variable ratio (>10) and reduce risk of overfitting. For microbiota analysis, we used procedures described previously, including filtering out rare taxa ($<0.1\%$ of relative abundance [RA] or detected in only a single sample) prior to downstream analysis [8]. Observed microbiota for each participant was classified into community types [12]. The distribution across community types by HR-HPV persistence status was assessed by Fisher's exact test. We compared RA and alpha diversity (supplementary materials) by HR-HPV persistence using the rank-sum test. Analyses used R version 4.4.2.

Ethics

Ethical approval was obtained from the National Institute for Medical Research (NIMR/HQ/R.8a/Vol.IX/2446), Weill Cornell Medicine (#1612017800), and Bugando Medical Centre/Catholic University for Health and Allied Sciences (CREC/171/2017). All participants provided written informed consent.

RESULTS

Within the initial cohort of 147 women, 96 without HIV co-infection were followed beyond 6 months and had paired baseline and end-line samples for HPV genotyping. The mean age was 32.7 ± 9.2 years, 75% were married, and the mean years of schooling were 5.7 ± 3.1 . Among these 96, 63 (66%) had any HPV type detected at baseline, of whom 51 (81%) had HR-HPV. The most frequent HR-HPV types were HPV-35, HPV-39, and HPV-68. Among those who had HR-HPV at baseline, 12 had persistence of the same HPV type at end-line. HR-HPV types that persisted were HPV-16, HPV-26, HPV-31, HPV-35 ($n = 2$), HPV-45 ($n = 2$), HPV-52, HPV-53 ($n = 3$), HPV-56, and HPV-73. One woman had persistence of 3 genotypes, and all others had 1. There were no differences in sociodemographic characteristics between women with versus without HR-HPV persistence, including age, age at first sex, and recent contraceptive use (Supplementary Table 1).

Thirty-nine women (41%) had schistosome infection at baseline compared with 21 women (22%) at end-line after

quarterly testing and treatment. There were no differences in rates of baseline HR-HPV infection, or overall HPV infections, between women with and without baseline schistosome infection. End-line schistosome infection was strongly associated with HR-HPV persistence on univariable analysis (odds ratio [OR] = 4.7 [1.3–16.5], $P = .017$). Gonorrhea and chlamydia infections tended to be more common among those with HR-HPV persistence (Figure 1A).

Baseline cervicovaginal microbiota were characterized in 86 women (90%). The RA of bacterial genera is depicted in stacked composition bar graphs (Figure 1B). Persistent HR-HPV was

associated with shifts in the distribution of community types ($P = .026$); women with persistent HR-HPV more frequently had *Gardnerella* dominance (33% vs 8% of women, $P = .049$), and although not significant, *Lactobacillus* dominance was less common (zero vs 26%, $P = .11$). The RA of *Gardnerella* was also higher in this group (31% vs 13%, $P = .031$). The predominant *Lactobacillus* species identified was *Lactobacillus iners* (2.6% vs 25.8%, $P = .069$); all other *Lactobacillus* species had mean RAs <1.5%.

On a prespecified subanalysis to examine potential contributions of schistosome infection by species, the odds of HR-HPV




Figure 1. Genital tract infections and cervicovaginal microbiota in women with and without persistent HR-HPV. A, Genital infections associated with HR-HPV persistence. B, Relative abundance of cervicovaginal microbiota in women without persistent HR-HPV (left side) and with persistent HR-HPV (right).

persistence remained elevated among women with schistosome infection living in *S. haematobium* endemic communities (OR = 2.7 [0.4–5.0], $P = .020$, $n = 42$), but did not differ between those with and without schistosome infection living in *S. mansoni* endemic communities ($n = 54$).

DISCUSSION

To our knowledge, this is the first study to document a robust increased odds of HR-HPV persistence in women with schistosome infection. Our group has previously reported altered cervicovaginal microbiota in schistosome infections [8], and the finding that cervicovaginal dysbiosis was also associated with HR-HPV persistence in our cohort further strengthens the veracity of our data given well-known linkages of dysbiosis with HR-HPV acquisition, persistence, and cervical dysplasia [7]. Understanding factors that drive HPV persistence is critical to improving cervical cancer prevention worldwide. This is particularly important in sub-Saharan Africa, where cervical cancer incidence and mortality are the world's highest [13]. Further, the high diversity of HPV types in Africa will lead to ongoing circulation of HR-HPV types even with wide use of prophylactic HPV vaccines [13]. To advance this discussion, we propose a causal pathway for contributors to HR-HPV persistence among women with schistosome infections.

Figure 2 depicts at least 3 plausible mechanisms by which schistosome infections may exacerbate cervical HPV persistence. First, egg migration through the genital mucosa—which occurs both in *S. haematobium* and *S. mansoni* infection—disrupts the genital epithelial barrier, altering mucosal gene expression [3]. Second, migration of immunogenic eggs evokes a Type 2 immune environment, with concomitant decreases in Type 1 antiviral responses, both in mucosa and systemically [3,4]. This altered Type 2 environment has been associated

with increased infectivity of HIV and reactivation of herpesvirus in *S. mansoni* infection [3, 4]. Notably, genital mucosal cytokine alterations are also linked with HPV persistence [14]. Third, we documented that cervicovaginal dysbiosis, marked by high microbial diversity or *Lactobacillus* deficiency, was associated with schistosome infection [8]. A meta-analysis of >100 000 women and robust human and animal data indicate that cervicovaginal dysbiosis potentiates HPV persistence and is itself potentiated by HPV [7]. Together, these data highlight the multiple genital mucosal effects of schistosome infection that may enhance HPV persistence. Future larger studies could use mediation analysis to test these pathways and quantify effects.

We report no association of *S. haematobium* with HR-HPV prevalence, suggesting that *S. haematobium* does not affect susceptibility to HR-HPV but could alter viral clearance. Our data contrast with findings from Zimbabwe in which women with FGS (defined as cervical lesions or eggs in the genital tract), versus women without, had more prevalent baseline HR-HPV, but not more persistent HR-HPV among the subset of 37 women (69%) examined after 5 years [15]. We posit that the study's low follow-up and nonspecific definition of FGS may explain its discrepant finding. We performed systemic antigenic detection of active *S. haematobium*, which does not guarantee genital tract involvement, and still found significant differences in genital mucosal HR-HPV persistence. This suggests that systemic *S. haematobium* infection involves the genital tract, whether through direct effects of eggs or indirect immune modulation, more frequently than previously recognized. Interestingly, soil-transmitted helminth infections in the gut have also been associated with increased cervical HPV prevalence and altered cervical cytokines [16].

This study has strengths and limitations. The relatively small size precluded multivariable analysis and potentially lowered power to detect other associations of HR-HPV. Furthermore,




Image created with BioRender.com and with guidance from Textor J et al, Int J Epi 2016 and DAGitty.net.

Figure 2. Proposed directed acyclic graph for factors contributing to HPV persistence and dysplasia in the setting of schistosome infections.

we could not establish the impact of anti-helminth treatment on HR-HPV persistence since all women were treated whenever schistosome infection was diagnosed. The association of end-line schistosome infection with HR-HPV persistence may be because women with end-line schistosome infection, despite quarterly testing and treatments, had greater schistosome burden and/or exposure. Key strengths include this study's hypothesis-driven testing and our finding that HR-HPV was associated with dysbiosis, consistent with other studies. Additionally, point estimates indicating higher HR-HPV persistence among individuals with chlamydia and gonorrhea underscore the reliability of our data.

In conclusion, our findings offer novel evidence that vaginal dysbiosis in schistosome-endemic settings may facilitate HR-HPV persistence. Our data suggest that *S. haematobium* infection may contribute to HR-HPV persistence and increase the risk of cervical cancer in areas in which these infections overlap.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online (<http://jid.oxfordjournals.org/>). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. The authors extend their heartfelt thanks to the participants for their willing and active participation in the study. The authors acknowledge the diligent efforts of the MSH study team and the laboratory team at the Mwanza Intervention Trials Unit/National Institute for Medical Research in Mwanza, Tanzania.

Authors' contributions. C. M.: conceptualization, investigation, formal analysis, writing—original draft. A. A. C.: formal analysis, writing—original draft. C. A.: investigation, project administration. S. C.: investigation, project administration. B. W. B.: investigation, visualization. S. K.: supervision. G. J. v. D.: supervision, methodology, resources. C. J. d. D.: investigation, resources. P. L. A. M. C.: supervision, methodology, resources. J. K. M.: conceptualization, interpretation. J. M. C.: supervision, interpretation. L. A. N.: supervision. V. A. M.: supervision. M. H. L.: formal analysis, visualization. J. A. D.: conceptualization, formal analysis, funding acquisition, investigation, methodology, writing—original draft. All authors reviewed and approved the final manuscript for submission.

Financial support. This work was supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (R01 AI 168306 and K24 AI 182638) and by the National Institutes of Health Fogarty International Center (D43 TW 011826).

Potential conflicts of interest. The authors declare no conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. World Health Organization. Schistosomiasis. 2023. <https://www.who.int/news-room/fact-sheets/detail/schistosomiasis>. Accessed 3 April 2025.
2. Kjetland EF, Poggensee G, Helling-Giese G, et al. Female genital schistosomiasis due to *Schistosoma haematobium*. Clinical and parasitological findings in women in rural Malawi. *Acta Trop* **1996**; 62:239–55.
3. Yegorov S, Joag V, Galiwango RM, et al. *Schistosoma mansoni* treatment reduces HIV entry into cervical CD4+ T cells and induces IFN- γ pathways. *Nat Commun* **2019**; 10:2296.
4. Reese TA, Wakeman BS, Choi HS, et al. Coinfection. Helminth infection reactivates latent γ -herpesvirus via cytokine competition at a viral promoter. *Science* **2014**; 345: 573–7.
5. Woodman CBJ, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. *Lancet* **2001**; 357:1831–6.
6. Sturt A, Omar T, Hansingo I, et al. Association of female genital schistosomiasis and human papillomavirus and cervical pre-cancer: a systematic review. *BMC Womens Health* **2025**; 25:2.
7. Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. *Am J Obstet Gynecol* **2019**; 221:9–18.e8.
8. Bullington BW, Lee MH, Mlingi J, et al. Cervicovaginal bacterial communities in reproductive-aged Tanzanian women with *Schistosoma mansoni*, *Schistosoma haematobium*, or without schistosome infection. *ISME J* **2021**; 15:1539–50.
9. Steenbergen RDM, Sinjders PJF, Heideman DAM, Meijer CJLM. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. *Nat Rev Cancer* **2014**; 14:395–405.
10. Abate A, Munshea A, Nibret E, et al. Characterization of human papillomavirus genotypes and their coverage in vaccine delivered to Ethiopian women. *Sci Rep* **2024**; 14:7976.
11. Corstjens PL, De Dood CJ, Kornelis D, et al. Tools for diagnosis, monitoring and screening of *Schistosoma* infections utilizing lateral-flow based assays and upconverting phosphor labels. *Parasitology* **2014**; 141:1841–55.
12. Anahtar M, Byrne E, Doherty K, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. *Immunity* **2015**; 42:965–76.

13. World Health Organization. Cervical cancer. 2024. <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer>. Accessed 3 April 2025.
14. Scott ME, Shvetsov YB, Thompson PJ, et al. Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. *Int J Cancer* **2013**; 133:1187–96.
15. Kjetland E, Ndhlovu P, Mduluza T, et al. The effects of genital *Schistosoma haematobium* on human papillomavirus and the development of cervical neoplasia after five years in a Zimbabwean population. *Eur J Gynaecol Oncol* **2010**; 31:169–73.
16. Gravitt PE, Marks M, Kosek M, et al. Soil-transmitted helminth infections are associated with an increase in human papillomavirus prevalence and a T-helper type 2 cytokine signature in cervical fluids. *J Infect Dis* **2016**; 213:723–30.